Takeda Development Center Americas, Inc. recalls Actoplus met XR (pioglitazone and metformin HCl, extended-release) tablets, 15 mg/1000 mg, Rx Only, 30 tablet bottle, Di
Recalled October 17, 2018 · FDA recall D-0026-2019 · Takeda Development Center Americas
Hazard
Defective Delivery System: tablets may be missing, in whole or in part, the laser drilled holes on the metformin core of the Actoplus met XR tablets. · FDA Class II
Units
7,248 bottles
Sold at
AR, LA, MS, NC, NJ, OH, PA, SC and Puerto Rico
Description
Defective Delivery System: tablets may be missing, in whole or in part, the laser drilled holes on the metformin core of the Actoplus met XR tablets.
Product
Actoplus met XR (pioglitazone and metformin HCl, extended-release) tablets, 15 mg/1000 mg, Rx Only, 30 tablet bottle, Distributed by: Takeda Pharmaceuticals America, Inc, Deerfield, IL 60015. NDC: 64764-510-30
Manufacturer(s)
Takeda Development Center Americas, Inc.
Source: U.S. Food and Drug Administration. Official recall notice on fda.gov →